The White House will nominate the new director of FDA, Tian Shili biology, for IPO in Hong Kong
Last Update: 2019-10-25
Search more information of high quality chemicals, good prices and reliable suppliers, visit
(2019 / 10 / 25) investigris bio's IPO capital in Hong Kong helps long-term development; policy increases add new ways for commercial production of ADC drugs in cdmo industry; AstraZeneca abandons the cooperation with Huang pharmaceutical in the development of savilitinib phase 3 renal cancer research; Bai Aotai is about to take the first imitation of adamumumab Letting go is also a kind of accomplishment
ADC drug development is very difficult
Do they have secrets? There seems to be no similar enterprise in China
Big data has been broken
Another bald head..
The HKEx has been busy recently.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to email@example.com
. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.